â– LECTURE OVERVIEW: Granulomatous inflammation is a highly organized, chronic inflammatory response designed to wall off and contain persistent, indigestible immunogenic foreign matter.
â– THE CYTOKINE CASCADES:
1. Antigen Presentation: Macrophages phagocytose the antigen (e.g., Mycobacterium tuberculosis or sarcoidosis proteins). They process and present antigens on MHC-II molecules to CD4+ T-lymphocytes.
2. Helper T Differentiation (IL-12): Macrophages secrete Interleukin-12 (IL-12), which binds to receptors on CD4+ T cells, driving their differentiation into pro-inflammatory Th1-type helper T cells.
3. Macrophage Mobilization (IFN-Gamma): Active Th1 cells secrete Interferon-gamma (IFN-g). IFN-g is the prime macrophage activator, morphologically converting them into epithelioid histiocytes.
4. Fusion & Shells (TNF-Alpha): Under the influence of TNF-alpha, epithelioid histiocytes fuse together to form giant multinucleated Langhans-type or foreign-body giant cells, surrounded by a cuff of lymphocytes and fibroblasts.
â– BIOCHEMICAL MECHANISMS:
At the molecular level, enzyme kinetics govern reaction rates. Competitive inhibitors raise apparent Michaelis constants without changing maximum speed, whereas noncompetitive inhibitors decrease maximum speed directly.
â– GENOMIC VARIANT CHARACTERISTICS:
Molecular profiling indicates that specific genetic subtypes exhibit varying levels of enzyme activity and drug-clearance efficiency.
[HY-BOARD-1110]
🌟 Dynamic Clinical Key:
TNF-alpha is the crucial cytokine required to preserve and maintain the integrity of a tuberculous granuloma. Chronic inflammatory arthritis patients treated with anti-TNF monoclonal antibodies (e.g., Infliximab, Adalimumab) risk rapid breakdown of these granulomatous 'shells', resulting in immediate reactivation of latent tuberculosis. Focus on rate-limiting regulatory steps for pharmacological design. Genetic screening profiles can help tailor precise therapeutic doses for optimal patient outcomes.